Clinical trials: Castration-Resistant Prostate Cancer (CRPC)
- Condition Castration-Resistant Prostate Cancer (CRPC)
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography / computed tomography (18F-NaF PET/CT) imaging as a method for determining treatment response in metastatic bone lesions in patients who…
- Trial name
- NCT02384382
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer
Prostate Cancer
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
The objective of this study was to compare the efficacy and safety of the combination therapy with enzalutamide + androgen deprivation therapy (ADT) and the combination therapy with flutamide + ADT in patients with castration…
- Trial name
- NCT02918968
- Testing
- Enzalutamide, Flutamide, Androgen deprivation therapy
- Where
- 47 sites in Japan
- Volunteers
- 206 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer.
- Trial name
- NCT01171898
- Testing
- ARN-509 (Phase 1), ARN-509 (Phase 2)
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Primary Objectives: To determine the maximum tolerated dose, and dose limiting toxicities of cabazitaxel administered as a 1-hour infusion every 3 weeks in combination with oral daily abiraterone acetate and prednisone in…
- Trial name
- NCT01511536
- Testing
- Cabazitaxel XRP6258, Abiraterone acetate, Prednisone 5 mg
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 38 people
- Sponsor
- Sanofi
Castration-Resistant Prostate Cancer (CRPC)
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.
- Trial name
- NCT01534052
- Testing
- Enzalutamide
- Where
- 7 sites in United States, Moldova and 1 more
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Prostatic Neoplasms, Castration-Resistant
Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
The primary objective was to confirm the effect of tasquinimod in delaying disease progression or death as compared with placebo in chemo-naïve patients with metastatic castrate-resistant prostate cancer (mCRPC).
- Trial name
- TasQ003 (NCT02057666)
- Testing
- Tasquinimod
- Where
- 36 sites in China, South Korea and 1 more
- Volunteers
- 146 people
- Sponsor
- Ipsen
Prostatic Neoplasms, Castration-Resistant
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
The overall aim of the trial is to investigate the safety and anti-tumour activity of an experimental drug BI 836845 taken together with the prostate cancer drug, enzalutamide, compared to enzalutamide given alone, in castrate…
- Trial name
- NCT02204072
- Testing
- BI 836845, Enzalutamide
- Where
- 27 sites in United States, Hong Kong and 6 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Castration Resistant Prostate Cancer
Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.
- Trial name
- NCT01540071
- Testing
- NRX 194204
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Io Therapeutics
Prostate Cancer, Castration Resistant Prostate Cancer
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease…
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
- Trial name
- COMET-1 (NCT01605227)
- Testing
- cabozantinib, prednisone
- Where
- 264 sites in United States, Australia and 12 more
- Volunteers
- 1,028 people
- Sponsor
- Exelixis
Prostate Cancer
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer
Multicenter open label, uncontrolled study that enrolled men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study.
- Trial name
- mCRPC (NCT01338012)
- Testing
- sipuleucel-T
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Dendreon
Prostate Cancer
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT00887198
- Testing
- Abiraterone acetate, Prednisone
- Where
- 134 sites in United States, Australia and 9 more
- Volunteers
- 1,088 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
To determine if the addition of radium-223 dichloride to standard treatment is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as painful fractures or bone pain which needs…
- Trial name
- ERA 223 (NCT02043678)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Abiraterone, Prednisone/Prednisolone
- Where
- 163 sites in United States, Australia and 17 more
- Volunteers
- 806 people
- Sponsor
- Bayer
Prostatic Neoplasms
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
The primary objective in this study is to evaluate bone scan response at Week 24 based on the quantified technetium-99 bone scan lesion area (BSLA).
- Trial name
- NCT02034552
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Abiraterone acetate, Prednisone
- Where
- 19 sites in United States
- Volunteers
- 68 people
- Sponsor
- Bayer
Bone Metastases, Castration-Resistant Prostate Cancer
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
The main purpose of this study is to establish a recommended dose of Alpharadin to be used in combination with docetaxel in patients with bone metastases from castration-resistant prostate cancer and to investigate safety and…
- Trial name
- NCT01106352
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel
- Where
- 7 sites in United States, France
- Volunteers
- 70 people
- Sponsor
- Bayer
Prostate Cancer, Castration Resistant Prostate Cancer
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Bone metastases and associated pain are a major cause of morbidity and mortality in castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
- Trial name
- COMET-2 (NCT01522443)
- Testing
- cabozantinib, mitoxantrone, prednisone
- Where
- 82 sites in United States, Australia and 3 more
- Volunteers
- 119 people
- Sponsor
- Exelixis
Prostatic Neoplasms
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 [PCWG2]) of apalutamide versus placebo in Chinese participants…
- Trial name
- NCT04108208
- Testing
- Apalutamide, Androgen-deprivation Therapy (ADT)
- Where
- 27 sites in China
- Volunteers
- 75 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
The purpose of this study was to evaluate the impact of concurrent versus sequential administration of abiraterone acetate plus prednisone on the ability to manufacture sipuleucel-T (by assessing sipuleucel-T product parameters)…
- Conditions
- Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT01487863
- Testing
- sipuleucel-T, abiraterone acetate
- Where
- 21 sites in United States
- Volunteers
- 69 people
- Sponsor
- Dendreon
Prostate Neoplasms, Prostate Cancer
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to establish the safety profile of oral (by mouth) abiraterone acetate and oral prednisone following short-term administration after standardized low-fat or high-fat meals to patients with metastatic…
- Trial name
- NCT01424930
- Testing
- Abiraterone, Prednisone
- Where
- 2 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Janssen-Ortho Inc., Canada
Prostate Cancer, Castration Resistant Prostate Cancer
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
This study was conducted in subjects in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms
- Trial name
- NCT01995058
- Testing
- cabozantinib, abiraterone, prednisone
- Where
- 20 sites in United States
- Volunteers
- 54 people
- Sponsor
- Exelixis
Prostatic Neoplasms
An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration-resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) repair anomalies.
- Trial name
- Galahad (NCT02854436)
- Testing
- Niraparib
- Where
- 110 sites in United States, Australia and 13 more
- Volunteers
- 289 people
- Sponsor
- Janssen Research & Development, LLC